JP2012515794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012515794A5 JP2012515794A5 JP2011548156A JP2011548156A JP2012515794A5 JP 2012515794 A5 JP2012515794 A5 JP 2012515794A5 JP 2011548156 A JP2011548156 A JP 2011548156A JP 2011548156 A JP2011548156 A JP 2011548156A JP 2012515794 A5 JP2012515794 A5 JP 2012515794A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- seq
- positions
- asparagine
- cysteine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 235000009582 asparagine Nutrition 0.000 claims 6
- 229960001230 asparagine Drugs 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 108060001064 Calcitonin Proteins 0.000 claims 4
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- 235000004279 alanine Nutrition 0.000 claims 4
- 235000003704 aspartic acid Nutrition 0.000 claims 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 4
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 4
- VSHJAJRPRRNBEK-LMVCGNDWSA-N eel calcitonin Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CS)[C@@H](C)O)C(C)C)CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C1=CN=CN1 VSHJAJRPRRNBEK-LMVCGNDWSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 108010068072 salmon calcitonin Proteins 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 3
- 229940024606 amino acid Drugs 0.000 claims 3
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims 3
- 239000004474 valine Substances 0.000 claims 3
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 241000972773 Aulopiformes Species 0.000 claims 1
- 102000055006 Calcitonin Human genes 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
- 239000004473 Threonine Substances 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 230000036528 appetite Effects 0.000 claims 1
- 235000019789 appetite Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 235000019515 salmon Nutrition 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20575009P | 2009-01-22 | 2009-01-22 | |
| US61/205,750 | 2009-01-22 | ||
| PCT/US2010/021872 WO2010085700A2 (en) | 2009-01-22 | 2010-01-22 | Treatment for obesity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012515794A JP2012515794A (ja) | 2012-07-12 |
| JP2012515794A5 true JP2012515794A5 (OSRAM) | 2013-03-07 |
| JP5753097B2 JP5753097B2 (ja) | 2015-07-22 |
Family
ID=42356411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011548156A Expired - Fee Related JP5753097B2 (ja) | 2009-01-22 | 2010-01-22 | 肥満の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US8076291B2 (OSRAM) |
| EP (1) | EP2389388B1 (OSRAM) |
| JP (1) | JP5753097B2 (OSRAM) |
| KR (1) | KR20110119707A (OSRAM) |
| CN (1) | CN102292346B (OSRAM) |
| AU (1) | AU2010206614B2 (OSRAM) |
| BR (1) | BRPI1006943A2 (OSRAM) |
| CA (1) | CA2750035C (OSRAM) |
| DK (1) | DK2389388T3 (OSRAM) |
| ES (1) | ES2622877T3 (OSRAM) |
| WO (1) | WO2010085700A2 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102292346B (zh) | 2009-01-22 | 2015-12-02 | 关键生物科学有限公司 | 肥胖的治疗 |
| JP2014502252A (ja) | 2010-09-28 | 2014-01-30 | アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー | 作用持続時間が増した改変ポリペプチド |
| US9533022B2 (en) | 2011-11-02 | 2017-01-03 | KeyBioscience A/S | Peptide analogs for treating diseases and disorders |
| MX351092B (es) * | 2011-11-02 | 2017-10-02 | Keybioscience Ag | Analogos peptidicos para tratar enfermedades y trastornos. |
| EP3095484B1 (en) * | 2011-11-02 | 2018-05-02 | KeyBioscience AG | Calcitonin mimetics for treating diseases and disorders |
| ES2640285T3 (es) * | 2012-04-19 | 2017-11-02 | Novo Nordisk A/S | Análogos de amilina humana |
| CN102964452B (zh) * | 2012-12-12 | 2015-09-09 | 黑龙江大学 | 用于治骨质疏松症和肥胖的msCT-rhLeptin融合蛋白及编码该融合蛋白的核酸 |
| CN102965327B (zh) * | 2012-12-12 | 2014-06-11 | 黑龙江大学 | msCT-rhLeptin融合蛋白转基因工程菌株 |
| WO2016034604A1 (en) | 2014-09-04 | 2016-03-10 | Novo Nordisk A/S | Novel amylin and calcitonin receptor agonist |
| GB201500263D0 (en) * | 2015-01-08 | 2015-02-25 | Keybioscience Ag | Calcitonin analogues for treating diseases and disorders |
| EA202092442A3 (ru) | 2016-06-07 | 2021-08-31 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| WO2018172984A1 (en) | 2017-03-23 | 2018-09-27 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| CN112839935A (zh) | 2018-09-26 | 2021-05-25 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
| KR102911883B1 (ko) | 2018-10-11 | 2026-01-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 인간 아밀린 유사체 폴리펩타이드 및 사용 방법 |
| TWI901926B (zh) | 2020-12-18 | 2025-10-21 | 美商美國禮來大藥廠 | 雙重澱粉素及降鈣素受體促效劑及其用途 |
| CA3266547A1 (en) | 2022-08-29 | 2024-03-07 | Eli Lilly And Company | COMPOSITIONS FOR ORAL ADMINISTRATION |
| WO2025240893A1 (en) | 2024-05-17 | 2025-11-20 | Eli Lilly And Company | 4-phenyl-1h-pyrazolo[3,4-b]pyridine-5-carboxamide derivatives as amylin and/or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
| US4708934A (en) | 1984-09-27 | 1987-11-24 | Unigene Laboratories, Inc. | α-amidation enzyme |
| US4764589A (en) | 1987-05-26 | 1988-08-16 | Rorer Pharmaceutical Corporation | [N-alpha-acyl,8-glycine, des-19-leucine]-calcitonin |
| US5789234A (en) | 1987-08-14 | 1998-08-04 | Unigene Laboratories, Inc. | Expression systems for amidating enzyme |
| US5364840A (en) * | 1989-12-05 | 1994-11-15 | Vical, Inc. | Synthetic calcitonin peptides |
| US5175146A (en) * | 1989-12-05 | 1992-12-29 | Vical, Inc. | Synthetic calcitonin peptides |
| US5527771A (en) * | 1991-01-10 | 1996-06-18 | Amylin Pharmaceuticals, Inc. | Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions |
| US5580953A (en) * | 1991-08-14 | 1996-12-03 | Amylin Pharmaceuticals, Inc. | Amylin antagonist peptides and uses therefor |
| US5527790A (en) | 1991-09-30 | 1996-06-18 | The University Of British Columbia | Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar |
| JPH083196A (ja) * | 1994-06-21 | 1996-01-09 | Sanwa Kagaku Kenkyusho Co Ltd | カルシトニン誘導体及びその用途 |
| DE726075T1 (de) * | 1995-02-08 | 1996-12-12 | Therapicon Srl | Nicht-inorganische pharmazeutische salzige Lösungen zur endonasale Verabreichung |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| CA2502764A1 (en) * | 1995-08-22 | 1997-03-06 | Japan Tobacco Inc. | Amide compounds |
| HUP0001272A3 (en) | 1997-04-16 | 2012-12-28 | Unigene Lab Inc | Direct expression of peptides into culture media |
| US6083480A (en) * | 1997-05-01 | 2000-07-04 | Diatide, Inc. | Calcitonin receptor binding reagents |
| US6086018A (en) | 1997-12-09 | 2000-07-11 | Mcdonnell Douglas Corporation | Interlocking assembly system for an aircraft cabin |
| JP2000290295A (ja) * | 1999-03-31 | 2000-10-17 | Asahi Chem Ind Co Ltd | Ｎ−アセチルグルコサミニルカルシトニン |
| CN1274830C (zh) * | 2001-12-14 | 2006-09-13 | 中国农业科学院生物技术研究所 | 一种新型鲑鱼降钙素类似物及其在植物油体中表达的方法 |
| CN1980954A (zh) * | 2004-02-11 | 2007-06-13 | 安米林药品公司 | 胰岛淀粉样多肽家族肽及其制备和使用方法 |
| DE602005021858D1 (de) | 2004-02-11 | 2010-07-29 | Amylin Pharmaceuticals Inc | Peptide der amylin familie, verfahren zu deren herstellung und verwendung |
| US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| GB0422644D0 (en) | 2004-10-12 | 2004-11-10 | Novartis Ag | Organic compounds |
| US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| US7445911B2 (en) | 2004-11-24 | 2008-11-04 | Unigene Laboratories Inc. | Enzymatic reactions in the presence of keto acids |
| US7671023B2 (en) * | 2005-03-31 | 2010-03-02 | Amylin Pharmaceuticals, Inc. | Amylin agonist for treating depression, anxiety disorder and schizophrenia |
| EP1907561B1 (en) | 2005-06-24 | 2013-08-28 | Unigene Laboratories, Inc. | Cell lines for expressing enzyme useful in the preparation of amidated products |
| US8377863B2 (en) | 2007-05-29 | 2013-02-19 | Unigene Laboratories Inc. | Peptide pharmaceutical for oral delivery |
| CN102292346B (zh) * | 2009-01-22 | 2015-12-02 | 关键生物科学有限公司 | 肥胖的治疗 |
-
2010
- 2010-01-22 CN CN201080005151.6A patent/CN102292346B/zh not_active Expired - Fee Related
- 2010-01-22 ES ES10733943.4T patent/ES2622877T3/es active Active
- 2010-01-22 US US12/692,502 patent/US8076291B2/en not_active Expired - Fee Related
- 2010-01-22 CA CA2750035A patent/CA2750035C/en not_active Expired - Fee Related
- 2010-01-22 DK DK10733943.4T patent/DK2389388T3/en active
- 2010-01-22 JP JP2011548156A patent/JP5753097B2/ja not_active Expired - Fee Related
- 2010-01-22 EP EP10733943.4A patent/EP2389388B1/en not_active Not-in-force
- 2010-01-22 AU AU2010206614A patent/AU2010206614B2/en not_active Ceased
- 2010-01-22 KR KR1020117018879A patent/KR20110119707A/ko not_active Ceased
- 2010-01-22 BR BRPI1006943-7A patent/BRPI1006943A2/pt not_active IP Right Cessation
- 2010-01-22 WO PCT/US2010/021872 patent/WO2010085700A2/en not_active Ceased
-
2011
- 2011-11-14 US US13/295,906 patent/US8217139B2/en not_active Expired - Fee Related
- 2011-11-14 US US13/295,936 patent/US8378067B2/en not_active Expired - Fee Related
-
2012
- 2012-07-09 US US13/544,256 patent/US8497347B2/en not_active Expired - Fee Related
-
2013
- 2013-06-28 US US13/930,438 patent/US9394342B2/en active Active
-
2016
- 2016-07-18 US US15/212,432 patent/US9833494B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2485135C2 (ru) | Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты) | |
| NZ628987A (en) | Extended recombinant polypeptides and compositions comprising same | |
| JP2013515057A5 (OSRAM) | ||
| JP2013543497A5 (OSRAM) | ||
| JP2006149365A5 (OSRAM) | ||
| JP2010222379A5 (OSRAM) | ||
| UA103154C2 (uk) | Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його | |
| EP3428182A3 (en) | Anti-inflammatory peptides and composition comprising the same | |
| JP2011502964A5 (OSRAM) | ||
| IN2014KN01713A (OSRAM) | ||
| IN2014KN01716A (OSRAM) | ||
| WO2009038026A1 (ja) | Ｃｔｌ誘導剤組成物 | |
| MX2008009493A (es) | Peptido novedoso y uso del mismo. | |
| JP2011509093A5 (OSRAM) | ||
| WO2011038900A3 (en) | Peptide analogues of glucagon for diabetes therapy | |
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| JP2017221201A5 (OSRAM) | ||
| EP2465935A3 (en) | Recombinant human interferon-like proteins | |
| RU2014122171A (ru) | Пептидные аналоги для лечения заболеваний и расстройств | |
| JP2004521123A5 (OSRAM) | ||
| NZ594268A (en) | Grass peptides for vaccine | |
| NZ609474A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| JP2012518669A5 (OSRAM) | ||
| EA201100459A1 (ru) | Композиции, включающие интерлейкин-1 и пептиды | |
| AU2022222674A9 (en) | Glucagon-like peptide-1 receptor antagonists |